NIA R01: Drug Repositioning and Combination Therapy for Alzheimer's Disease
Funds researchers combining computational and experimental approaches to test repositioned drugs for Alzheimer's disease treatment through NIH R01 grants.
The National Institute on Aging (NIA), part of the National Institutes of Health (NIH) under the Department of Health and Human Services, administers this R01 grant through the PAR-25-374 Notice of Funding Opportunity (NOFO). It sits under the ACTDRx AD (Advancing Combination Therapy and Drug Repurposing for Alzheimer's Disease) program, a cross-disciplinary initiative using translational bioinfor…
Translational bioinformatics and preclinical experimental work to identify and test drugs (individually or in combination) that may treat Alzheimer's disease and related dementias. Includes PK/PD modeling, mouse models, cell-based models, iPSCs, organoids, and non-pharmacologic interventions.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up
Guides for this application
All guides →NIH Biosketch Guide: Format, SciENcv Steps, and Examples
Learn what an NIH biosketch is, how the format works, what to prepare for SciENcv, and how startup teams should avoid common biosketch mistakes.
Write proposalHow to Write a Specific Aims Page
Learn how to write a specific aims page for NIH, SBIR-adjacent, and translational R&D grants, with structure, reviewer logic, examples, and common mistakes.
Where to applyGrants for Biotech Startups: NIH, NSF, SBIR/STTR, and Non-Dilutive Funding
A practical guide to grants for biotech startups, including NIH SBIR/STTR, NSF, translational funding, evidence, regulatory readiness, and budgets.
Write proposalHow to Write a Grant Proposal Reviewers Can Score
Learn how to write a grant proposal around reviewer criteria, evidence, work packages, budget logic, and commercialization for deeptech and R&D funding.
More from NIA
All grants from this funder →2026 NIA Mentorship Prize Competition
🇺🇸NIA · United States
Pays $100,000 to each of up to six faculty mentors recognized for outstanding aging-research mentorship.
NIA SBIR Phase I
🇺🇸NIA · United States
Supports small businesses developing aging and memory technologies at the feasibility stage.
NIA SBIR Phase II
🇺🇸NIA · United States
Funds small businesses advancing aging biology and Alzheimer's disease technologies through full development execution.
NIA STTR Phase I
🇺🇸NIA · United States
Supports small businesses partnering with universities on aging innovation at feasibility stage.
NIA Alzheimer's Drug-Development Program
🇺🇸NIA · United States
Funds collaborative research alliances that accelerate Alzheimer's drug development in the United States.
NIA Start-Up Challenge
🇺🇸NIA · United States
Funds US entrepreneurs and small businesses developing healthy-aging technologies through NIA's Start-Up Challenge cash prizes and accelerator.
Similar grants
Browse the directory →
NCATS Clinical Trial Readiness for Rare Diseases
🇺🇸NCATS · United States
Funds U.S. researchers and companies generating natural history data, biomarkers, and outcome measures needed to design clinical trials for rare diseases.
NATIF Grant and Commissioned S&T Tasks
🇻🇳NATIF · Vietnam
Funds Vietnamese enterprises and research partners developing technology through NATIF grant and commissioned S&T tasks.
NCATS Preclinical Proof of Concept Studies for Rare Diseases
🇺🇸NCATS · United States
Funds U.S. researchers and companies conducting preclinical efficacy studies to advance therapeutic candidates for rare diseases toward IND applications.
AI Predictive Biomarkers for Chronic Diseases
🇪🇺European Commission · European Union
Funds trustworthy AI biomarker methods that predict chronic-disease progression and treatment response for personalised care.
WIPANO Standards Participation for Companies
🇩🇪BMWE · Germany
Funds German companies with up to 1,000 employees taking part in national, European, and international standardization committees through WIPANO.
Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants
NIH · United States
Funds an addition to an existing NIH grant, to take a cancer biomarker assay from working in the lab to working in the clinic.